"Apple's (AAPL) glory days are now behind it," said FBN's Shebly Seyrafi on Thursday morning with the stock at $450. On Sept. 13 - the day after the iPhone 5 launch and the shares at $680 - Seyrafi reiterated a Buy rating and boosted his price target to $1,000. (FBN now maintains an Outperform on Apple with a lowered target of $650.) [View news story]
Crapple is Kaput..Cook and his crew are greedy. Cook knew they missed their numbers and should of did a buy back and the biggest dividend of all companies!..Buy put's and short it..This Market is flying but will land soon enough..
Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday. [View news story]
Does anyone have a idea why SRPT going to sell shares? Is this good.bad or ugly for the longs in this position?
Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday. [View news story]
We are all here to make money but I do hope for the sake of these kids this drug works. You can almost feel guilty if you short this company.I hope they find a cure at the end of it all..
Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday. [View news story]
Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA yesterday approved its weight-loss drug Qnexa/Qsymia. Shares had fallen sharply prior to the announcement. Also this morning, rivals Arena (ARNA) -5.9% and Orexigen Therapeutics (OREX) +3.2%. [View news story]
ARNA is held mostly by the common person.VVUS is held mostly by the institutions..I still think Arna will prevail and this company will double.Wall street games again...
Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around zero after USA Today reports that the FDA has approved its Qnexa/Qysemia diet drug. However, no other news organizations appear to have reported the story, and it's not on the FDA website. Update: the linked-story in this MC seems to have been taken down. Vivus shares -0.6%. [View news story]
USAToday and FOX get there news from same source...
Cramer's Mad Money - Arena's Teachable Moment (7/11/12) [View article]
Cramer is a hypocrite.It is sad that he has a audience that follows him..WAKE UP PEOPLE....ARNA is a buy on the dips,the drug is in and there is no speculation in that...
Vivus: A New Twist On The Qnexa Story [View article]
The only thing I know is Jim Cramer is knocking ARNA. He is yelling from his pulpit about hallucination side effects from ARNA. Jim should look at the side effects of VVUS..
All I know that any new drug that hit's the market will make billions...ARNA is a head of this game and VVUS still has to get approved..
Jim Cramer dampens some of the excitement surrounding Arena (ARNA -4.1%), saying that the company's Belviq diet drug won't make as much money as people think. Cramer notes that Arena will receive just 40% of the revenues from treatment, which is anyway not as effective as initially thought, nor as good as Vivus' (VVUS) yet-to-be-approved Qnexa. [View news story]
Seagate (STX) -5.4% and Western Digital (WDC) -3.7% following downgrades to Hold from ThinkEquity. The firm says checks indicate emerging markets PC demand is weakening, and what's bad from the PC market is bad for the hard drive market. While commentary about soft U.S./Euro PC demand has been widespread, an emerging markets slowdown seems to be a wrinkle the market hasn't yet priced in. [View news story]
catastrophic flood? than surplus in drives? Barron's upgrade? Than added to S&P-500..What's going on here?
Lose-Lose Bets With Arena's FDA Approval [View article]
All I know is it's a break-through drug after 13 yrs. Did not reach it's 52 week high and is being shorted to death again. I took my long profits and lost on my calls but still was green in the long run,tomorrow is another day...
The only thing I know is that Y.T.D if you shorted most of the stocks mentioned here,you made out big. The market is bi-polar and i am getting bi-polar...
"Apple's (AAPL) glory days are now behind it," said FBN's Shebly Seyrafi on Thursday morning with the stock at $450. On Sept. 13 - the day after the iPhone 5 launch and the shares at $680 - Seyrafi reiterated a Buy rating and boosted his price target to $1,000. (FBN now maintains an Outperform on Apple with a lowered target of $650.) [View news story]
Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday. [View news story]
Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday. [View news story]
Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday. [View news story]
Fossil (FOSL): Q2 EPS of $0.92 beats by $0.14. Revenue of $636M (+14.3% Y/Y) beats by $1.5M. (PR) [View news story]
Should Facebook Make Users Pay? [View article]
Cramer's Mad Money - Arena's Teachable Moment (7/11/12) [View article]
Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA yesterday approved its weight-loss drug Qnexa/Qsymia. Shares had fallen sharply prior to the announcement. Also this morning, rivals Arena (ARNA) -5.9% and Orexigen Therapeutics (OREX) +3.2%. [View news story]
Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around zero after USA Today reports that the FDA has approved its Qnexa/Qysemia diet drug. However, no other news organizations appear to have reported the story, and it's not on the FDA website. Update: the linked-story in this MC seems to have been taken down. Vivus shares -0.6%. [View news story]
Cramer's Mad Money - Arena's Teachable Moment (7/11/12) [View article]
Vivus: A New Twist On The Qnexa Story [View article]
All I know that any new drug that hit's the market will make billions...ARNA is a head of this game and VVUS still has to get approved..
Jim Cramer dampens some of the excitement surrounding Arena (ARNA -4.1%), saying that the company's Belviq diet drug won't make as much money as people think. Cramer notes that Arena will receive just 40% of the revenues from treatment, which is anyway not as effective as initially thought, nor as good as Vivus' (VVUS) yet-to-be-approved Qnexa. [View news story]
Seagate (STX) -5.4% and Western Digital (WDC) -3.7% following downgrades to Hold from ThinkEquity. The firm says checks indicate emerging markets PC demand is weakening, and what's bad from the PC market is bad for the hard drive market. While commentary about soft U.S./Euro PC demand has been widespread, an emerging markets slowdown seems to be a wrinkle the market hasn't yet priced in. [View news story]
Lose-Lose Bets With Arena's FDA Approval [View article]
Shorting A Stock? 6 Useful Tips [View article]